Key Points – Icon’s Q2 revenue rose 1.2% year over year to $2.1 billion, while adjusted EBITDA increased to $327.2 million and adjusted EPS reached $2.56.
Management reaffirmed full-year 2026 guidance and expects sequential EBITDA-dollar improvement in the second half. – Bookings strengthened significantly, with gross business wins up 24% year over year to $3.7 billion, net bookings of $3.1 billion and an overall net book-to-bill ratio of 1.51x
Direct-fee bookings produced a solid 1.2x net book-to-bill ratio. – Higher pass-through activity pressured reported margins, reducing adjusted EBITDA margin to 15.9% from 20.5% a year earlier. Icon generated $238.9 million in free cash flow and plans to resume share repurchases while investing in China expansion and AI-enabled clinical-trial operations. – 3 Healthcare Pathbreakers With Long-Term Tailwinds Icon (NASDAQ:ICLR) reported second-quarter 2026 revenue growth and strong bookings as higher pass-through activity supported the top line, while the company continued to manage business-mix pressures affecting reported margins. Chief Executive Officer Barry Balfe said the contract research organization’s results reflected a “positive demand environment, strong bookings, and disciplined cost management.” Revenue rose 1.2% year over year and 1.4% sequentially to $2.1 billion.
Adjusted EBITDA increased 3% from the first quarter to $327.2 million, while adjusted diluted earnings per share totaled $2.56. – Should You Bring The Luck Of The Irish To Your Investmets? The company reaffirmed its full-year 2026 financial guidance. Management said higher pass-through activity could influence where Icon lands within its revenue range and affect reported margin percentages, while its focus remains on sequential improvement in EBITDA dollars.